An Open-Label, Multi-Center Phase 1/2 study of Surufatinib in Combination with Gemcitabine in Pediatric Patients with Recurrent or Refractory Solid Tumors COG ADVL2121

Grant

Total Award Amount

  • 57400.00
  • Direct Costs

  • 42206.00
  • Sponsor Award Id

  • Contributor

  • Elizabeth Alva   Investigator  
  • Emily Johnston   Investigator  
  • Jamie Aye   Principal Investigator  
  • Kimberly Whelan M.D.   Investigator